MA43755A - Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte - Google Patents

Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte

Info

Publication number
MA43755A
MA43755A MA043755A MA43755A MA43755A MA 43755 A MA43755 A MA 43755A MA 043755 A MA043755 A MA 043755A MA 43755 A MA43755 A MA 43755A MA 43755 A MA43755 A MA 43755A
Authority
MA
Morocco
Prior art keywords
host
graft
prevention
treatment
methods
Prior art date
Application number
MA043755A
Other languages
English (en)
Inventor
John E Ford
Jessica A Sachs
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA43755A publication Critical patent/MA43755A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA043755A 2016-03-14 2017-03-13 Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte MA43755A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14
US201662420825P 2016-11-11 2016-11-11

Publications (1)

Publication Number Publication Date
MA43755A true MA43755A (fr) 2018-11-28

Family

ID=58455657

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043755A MA43755A (fr) 2016-03-14 2017-03-13 Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte

Country Status (12)

Country Link
US (1) US20190077868A1 (fr)
EP (1) EP3430053A1 (fr)
JP (3) JP2019512493A (fr)
KR (2) KR102667332B1 (fr)
CN (2) CN109153721A (fr)
AU (2) AU2017234010B2 (fr)
BR (1) BR112018068625A2 (fr)
CA (1) CA3017758A1 (fr)
IL (1) IL261767B1 (fr)
MA (1) MA43755A (fr)
MX (2) MX2018011025A (fr)
WO (1) WO2017160700A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3430052A2 (fr) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
WO2017218434A1 (fr) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Méthode de traitement de maladie intestinale inflammatoire
IL270201B2 (en) * 2017-04-28 2026-05-01 Millennium Pharm Inc A method for treating childhood disorders
EP4720125A1 (fr) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Compositions d'anticorps anti-intégrine alpha4beta7 et procédés d'utilisation
EP4762093A1 (fr) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Protéines de liaison à l'intégrine alpha 4 bêta 7 et procédés d'utilisation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
DOP2005000002A (es) 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
ZA200803016B (en) * 2005-09-29 2009-10-28 Elan Pharmaceuticals Inc Wyeth Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1948691A1 (fr) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. IMMUNOGLOBULINE HUMANISEE REACTIVE AVEC L INTEGRINE a4ß7
PE20120497A1 (es) 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
DK2637672T3 (en) * 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
JP7105188B2 (ja) * 2015-08-25 2022-07-22 ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン 幹細胞移植方法
EP3430052A2 (fr) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Méthode de traitement de la réaction du greffon contre l'hôte (gvd)

Also Published As

Publication number Publication date
KR20180117195A (ko) 2018-10-26
US20190077868A1 (en) 2019-03-14
MX2024008740A (es) 2024-07-23
WO2017160700A1 (fr) 2017-09-21
JP2025118642A (ja) 2025-08-13
AU2017234010B2 (en) 2024-06-13
MX2018011025A (es) 2019-01-10
BR112018068625A2 (pt) 2019-07-30
KR102667332B1 (ko) 2024-05-20
AU2017234010A1 (en) 2018-09-27
KR20240074903A (ko) 2024-05-28
AU2024203289A1 (en) 2024-08-01
CN109153721A (zh) 2019-01-04
JP2019512493A (ja) 2019-05-16
CA3017758A1 (fr) 2017-09-21
IL261767B1 (en) 2026-07-01
KR102830639B1 (ko) 2025-07-07
EP3430053A1 (fr) 2019-01-23
IL261767A (en) 2018-10-31
JP2022137024A (ja) 2022-09-21
CN117298268A (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
EP3534907A4 (fr) Compositions et méthodes de traitement d'une maladie hépatique
EP3490582A4 (fr) Méthodes et compositions de traitement de maladie.
EP3386520A4 (fr) Méthodes de traitement d'une maladie ou d'un trouble oculaire
EP3645121A4 (fr) Méthodes de traitement de la maladie de huntington
EP3458589A4 (fr) Compositions et méthodes de traitement de la maladie de huntington
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA43374A (fr) Méthodes de traitement de tumeurs malignes
EP3452166A4 (fr) Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blépharite
EP3515505A4 (fr) Traitement vaa de la maladie de huntington
EP3294761A4 (fr) Compositions et méthodes de traitement et de prévention de l'infection pare. coli
EP3298140A4 (fr) Compositions pour le traitement d'états de calcification pathologique, et méthodes les utilisant
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
EP3402533A4 (fr) Méthodes et compositions pour le traitement d'une maladie neurologique
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
EP3294345A4 (fr) Formulations de tpp1 et méthodes de traitement de la maladie cln2
EP3432891A4 (fr) Méthodes de traitement et de prévention d'une infection à c. difficile
EP3846830A4 (fr) Méthodes et compositions pour le traitement de maladie musculo-squelettiques
EP3393468A4 (fr) Méthodes pour le traitement d'une maladie immunodéficiente
EP3471722A4 (fr) Composés et méthodes pour la prévention et/ou le traitement du cancer
IL266871A (en) Modified oligonucleotides for the treatment of polycystic kidney disease
EP3592355A4 (fr) Méthodes de traitement et/ou de prévention de la kératose actinique
MA46967A (fr) Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique